Search bioRxiv⌕ Search

Biology subjects

Hu, Y.-T.

Publications and source records attributed to Hu, Y.-T..

2 recordsLinked to original sources

CASTLE: a training-free foundation-model pipeline for cross-species behavioral classification

Accurately and efficiently quantifying animal behavior at scale without intensive manual labeling is a long-standing challenge for neuroscience and ethology. Keypoint-based tracking emphasizes simplicity and efficiency but loses the richness of posture and context, while emerging foundation models capture pixel-level details, yet often require nontrivial efforts of retraining and can be more sensitive to backgrounds or lighting. Here, we present CASTLE, a training-free pipeline that addresses all these issues by synergistically combining foundation models for segmentation, tracking, and feature extraction. By isolating regions-of-interest (ROI), CASTLE first generates "focused (ROI-masked)" and orientation-invariant latent features, capturing rich postural details in zero-shot, fine-tuning-free manners. Following ROI isolation, CASTLE, through an interactive "Behavior Microscope" module, supports hierarchical clustering, for progressive, human-in-the-loop embedding and clustering. This enables raw-image-assisted discovery of behavioral classes without predefined categories. Across mice, Drosophila and C. elegans, CASTLE matches expert class annotations (>90%), reveals disease-relevant phenotypes in Parkinsonian mouse models. By eliminating purpose-specific model training and providing a raw-image-informed accessible workflow, CASTLE offers a scalable framework for interpretable, cross-species behavioral phenotyping.

neuroscience↗

CRISPR/Cas9-based disease modelling and functional correction of Interleukin 7 Receptor alpha Severe Combined Immunodeficiency in T-lymphocytes and hematopoietic stem cells

Interleukin 7 Receptor Severe Combined Immunodeficiency (IL7R-SCID) is a life-threatening disorder caused by homozygous mutations in the IL7RA gene. Defective IL7R expression in humans hampers T cell precursors proliferation and differentiation during lymphopoiesis resulting in absence of T cells in newborns, who succumb to severe infections and death early after birth. Previous attempts to tackle IL7R-SCID by viral gene therapy have shown that unregulated IL7R expression predisposes to leukaemia, suggesting the application of targeted gene editing to insert a correct copy of the IL7RA gene in its genomic locus and mediate its physiological expression as a more feasible therapeutic approach. To this aim, we have first developed a CRISPR/Cas9-based IL7R-SCID disease modelling system that recapitulates the disease phenotype in primary human T cells and hematopoietic stem and progenitor cells (HSPCs). Then, we have designed a knock-in strategy that targets IL7RA exon 1 and introduces via homology directed repair a corrective, promoterless IL7RA cDNA followed by a reporter cassette through AAV6 transduction. Targeted integration of the corrective cassette in primary T cells restored IL7R expression and rescued functional downstream IL7R signalling. When applied to HSPCs further induced to differentiate into T cells in an Artificial Thymic Organoid system, our gene editing strategy overcame the T cell developmental block observed in IL7R-SCID patients, while promoting full maturation of T cells with physiological and developmentally regulated IL7R expression. Finally, genotoxicity assessment of the CRISPR/Cas9 platform in HSPCs using biased and unbiased technologies confirmed the safety of the strategy, paving the way for a new, efficient, and safe therapeutic option for IL7R-SCID patients.

molecular biology↗